Daniel Heller

Daniel Heller is a Professor at Cornell University's Graduate School of Medical Sciences and Head of the Cancer Nanotechnology Laboratory at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. His interdisciplinary work develops nanotechnologies to revolutionize cancer research, diagnosis, and treatment through engineering innovation.

Education:

• Bachelor of Arts in History, Rice University (2000)
• PhD in Chemistry, University of Illinois at Urbana-Champaign (2010)
• Damon Runyon Cancer Research Foundation Postdoctoral Fellowship, MIT Koch Institute (2012)

Dr. Heller pioneers cancer nanotechnology with three core research pillars: precision nanomedicines for targeted drug delivery (including blood-brain barrier-penetrating carriers), AI-powered diagnostic sensors for early cancer detection via implantable/wearable platforms, and nanosensors accelerating drug discovery. His lab integrates machine learning with quantum-defect-modified carbon nanotubes to detect multi-analyte cancer fingerprints in serum, enabling real-time biomarker monitoring for high-risk patients and treatment response assessment.

Analysis of his recent publications reveals a strategic shift toward clinical translation, with 2021-2023 work focusing on ovarian cancer detection systems and brain metastasis therapies. His Nature Biomedical Engineering (2022) study demonstrates how AI-enhanced nanosensors achieve unprecedented sensitivity in liquid biopsies, while his Nature Materials (2023) paper establishes a mechanistic foundation for nanocarrier-mediated CNS drug delivery—highlighting convergence of nanotechnology, computational biology, and oncology.

Scientific Awards:

• College of Liberal Arts and Sciences Young Alumni Award, University of Illinois (2024)
• Life Sciences Invention of the Year, UM Ventures (2023)
• American Institute for Medical and Biological Engineering (AIMBE) Fellow (2021)
• Pharmacology Teaching and Mentoring Award, Weill Cornell Graduate School (2020)
• CRS Nanomedicine Junior Faculty Award and American Cancer Society Research Scholar (2018)
• Pershing Square Sohn Prize (2017)
• Kavli Fellow, National Academy of Science (2015)

Dr. Heller actively mentors graduate students in Pharmacology and Physiology programs, evidenced by his 2020 Teaching Award. His research is funded by competitive grants including the American Cancer Society Research Scholar award and Pershing Square Sohn Prize, supporting high-risk translational projects like implantable sensor clinical validation and next-generation nanocarrier development for treatment-resistant cancers.

The Heller Lab operates as a multidisciplinary engine within MSKCC's Sloan Kettering Institute, combining engineers, chemists, and biologists with clinical collaborators. Current initiatives focus on translating ovarian cancer detection platforms to human trials and developing closed-loop therapeutic systems that auto-adjust dosing based on real-time biomarker feedback—positioning nanotechnology at the forefront of precision oncology.